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ABSTRACT 
 
Objectives 
 
In this study, we sought to investigate whether there was any association between genetically-regulated gene 
expression (as predicted using various reference panels) and anti-TNF treatment response (change in erythrocyte 
sedimentation rate, ESR) using 3,158 European ancestry rheumatoid arthritis patients. 
 
Methods 
 
The genetically-regulated portion of gene expression was estimated in the full cohort of 3,158 subjects (as well 
as within a sub-cohort consisting of 1,575 UK patients) using the PrediXcan software package with three different 
reference panels. Estimated expression was tested for association with anti-TNF treatment response. As a 
replication/validation experiment, we also investigated the correlation between change in ESR with measured 
gene expression at the Interleukin 18 Receptor Accessory Protein (IL18RAP) gene in whole blood and 
synovial tissue, using an independent replication data set of patients receiving conventional synthetic disease 
modifying anti-rheumatic drugs, with directly measured (via RNA sequencing) gene expression. 
 
Results 
 
We found that predicted expression of IL18RAP showed a consistent signal of association with treatment 
response across the reference panels. In our independent replication data set, IL18RAP expression in whole 
blood showed correlation with the change in ESR between baseline and follow-up (r = −0.35, p = 0.0091). 
Change in ESR was also correlated with the expression of IL18RAP in synovial tissue (r =−0.28, p = 
0.02). 
 
Conclusion 
 
Our results suggest that IL18RAP expression is worthy of further investigation as a potential predictor of 
treatment response in rheumatoid arthritis that is not specific to a particular drug type. 
 
Keywords: Rheumatoid Arthritis, Treatment, Pharmacogenetics 
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INTRODUCTION 
 
Tumour necrosis factor α inhibitors (anti-TNFs) are the most commonly-prescribed second-line 
drugs for conventional synthetic Disease Modifying Anti-Rheumatic Drug (csDMARD)-resistant 
rheumatoid arthritis (RA) patients. However, patients show a significant non-response rate to 
anti-TNF treatment1, 2. With recent advances in microarray and RNA sequencing (RNA-Seq) 
technologies, it is hypothesised that gene expression profiling might inform our understanding of 
the heterogeneity of responses to treatment in RA3. Indeed, Tanino et al.4 identified ten genes 
predictive of response to the anti-TNF antibody Infliximab, based on a transcriptome analysis of 
white blood cells from RA patients, while Julia` et al.5 identified an eight-gene predictor model from 
microarray gene expression analysis on whole blood RNA samples from RA patients. Previously, 
using a microarray analysis of mononuclear cell RNAs, Lequerre´ et al.6  was able to perfectly separate 
responders to Infliximab from non-responders. 
However, when studying a large number of patients, measuring gene expression at a genome- 
wide scale might not be financially feasible, as RNA-seq remains more expensive than genome-wide 
genotyping approaches. The PrediXcan method/software package7 is a cost-effective approach for 
estimating the genetically-regulated portion of gene expression at each gene from a genome-wide 
set of genes. PrediXcan estimates the component of a gene’s expression determined by an in- 
dividual’s SNP genotypes (at SNPs in the vicinity of the gene), and then tests for association 
between the predicted expression and the phenotype. The estimation of gene expression is per- 
formed using whole-genome tissue-dependent prediction models trained with reference panels that 
have both SNP and gene expression data. Here, we applied PrediXcan to data on RA patients 
receiving anti-TNF treatment from the MAximising Therapeutic Utility for Rheumatoid Arthritis 
(MATURA) consortium8, focussing on testing the association between the change in erythrocyte 
sedimentation rate (ESR) and predicted gene expression. We elected to focus on change in ESR 
as an objective measure of response that has been shown to have higher heritability than other 
measures of response9. 
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METHODS 
 
UK data set 
 
The UK data set was comprised of imputed genome-wide SNP genotype data (9,084,265  SNPs)  for up  to 
1583 patients receiving anti-TNF treatment from the MATURA consortium; this corresponds to 
the “anti-TNF, ESR data set” previously described by Cherlin et al.10 Quality control (QC) on the 
imputed SNP data was performed using standard procedures outlined by Anderson et al.11 
Individuals were excluded if the reported sex did not match the sex assessed by genotype, and 
samples with elevated missingness rate, outlying heterozygosity rate, outlying ethnicity and 
relatedness were also excluded. SNPs were excluded if they had a post-imputation INFO score 
< 0.8. Genotype hard calls were set to missing if the posterior probability was < 0.9. The data 
was filtered by minor allele frequency (MAF > 0.01), Hardy-Weinberg disequilibrium (p > 
0.000001) and missing genotype rate (<0.05). The SNP genotypes were encoded according to the 
number of copies of the minor allele possessed. The phenotype was defined as the difference 
between the follow-up ESR measure (measured at 6 months, or 3 months if this was not 
available) and the baseline ESR measure on the log scale, that is, log(ESRf u) − log(ESRbl). This 
difference was then adjusted (by taking as the final phenotype the standardised residuals from a 
linear regression, carried out in the statistical software package R) for baseline ESR, drug type (a 5-
level categorical variable indicating Adalimumab, Etanercept, Infliximab, Certolizumab	pegol	and	 Golimumab), a separate binary indication of whether or not patients received another 
DMARD in addition to the anti-TNF treatment, gender and the first ten principal components 
(PCs) of the SNP genotypes. The final post-QC data set was comprised of 1,575 individuals and 
4,542,023 SNPs. 
 
Expanded European ancestry data set 
 
An expanded European ancestry data set was constructed, consisting of imputed genotype data 
at 4,498,586 genome-wide SNPs for 3158 patients. This expanded data set consisted of a 
combination of the original (1,575 patient) UK data set and a separate independent data set of 
1,583 US and EU patients, corresponding to a subset (to which we were granted access) of the 
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patients from a pre-existing international collaboration formed to study the genetics of response 
to TNFi agents12. The same QC procedures were performed separately on the 1,583 US/EU 
patients, and their post-QC SNP genotype data were merged with the data for the 1,575 UK 
patients. In this combined European ancestry data set, the phenotype, defined as the difference 
between the follow-up ESR measure and the baseline ESR measure on the log scale, was adjusted 
for the baseline ESR measure on the log scale (log(ESRbl)) and the first three PCs (which was 
found sufficient to produce no inflation in the genome-wide set of test statistics for association 
between SNPs and phenotype) and subsequently adjusted for gender; other covariates were not 
available. The standardised residuals after all adjustments were then taken as the final phenotype. 
 
Replication data set 
 
The replication dataset consisted of 90 treatment-naive early rheumatoid arthritis patients fulfill- 
ing the 2010 ACR/EULAR RA Classification Criteria from the Pathobiology of Early Arthritis 
Cohort (PEAC), in whom ultrasound-guided synovial biopsies (n=87 post-QC) and whole blood 
samples (n=67) were subject to RNA-sequencing as previously described13. Notably both synovial 
biopsies and blood samples were taken prior to patients receiving any disease modifying treatment 
such as corticosteroids. 1µg of total RNA was used as an input material for library preparation 
using TruSeq RNA Sample Preparation Kit v2 (Illumina). Generated libraries were amplified 
with 10 cycles of PCR. Size of the libraries was confirmed using 2200 TapeStation and High 
Sensitivity D1K screen tape (Agilent Technologies) and concentration was determined by qPCR 
based method using Library quantification kit (KAPA). Multiplexed libraries (five per lane) were 
sequenced on Illumina HiSeq2500 to generate 50 million paired-end 75 base pair reads. Transcript 
abundance was derived using Kallisto v0.43.0 and tximport 1.4.0 using GENCODE v24/GRCh38 
as reference, and transformed to regularised log expression (RLE) using DESeq2 1.14.1. RNA-Seq 
data have been deposited in ArrayExpress under Accession code E-MTAB-6141. Genotyping and 
QC was performed using the same methodology as for the UK data set as described above. Ex- 
pression quantitative trait locus (eQTL) analysis on PEAC blood RNA-seq samples was performed 
using the matrix eQTL package in R14 using 4 principal components to adjust for ancestry and 4 
probabilistic estimation of expression residuals (PEER) calculated as per Stegle et al.15 as model 
covariates. 
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Discovery analysis based on predicted gene expression 
 
PrediXcan was applied to both the UK data set and the expanded European ancestry data set. In 
PrediXcan, an elastic net prediction model is built using a reference panel containing SNP and gene 
expression data. This model is then used to predict expression levels in the analysis cohort on 
the basis of the measured genotypes, and the resulting predicted expression levels are tested 
for association with the outcome of interest. We applied PrediXcan using three reference 
panels: (i) a MATURA reference panel comprising 210 MATURA samples (a subset of the UK 
samples used later for testing), for which SNP and gene expression data were available8); (ii) a 
GTEx reference panel for which PrediXcan provides pre-calculated models; this panel comprises 
338 samples from the Genotype- Tissue Expression Consortium16; (iii) a DGN reference panel for 
which PrediXcan provides pre- calculated models; this panel comprises 922 samples from the 
Depression Genes and Networks Consortium17. 
To construct the MATURA reference panel, we used 33,170 QC-ed and batch-adjusted18 gene 
expression probes from the Illumina HT-12 Gene Expression Beadchip, measured in whole-blood 
at baseline in 210 patients, together with QC-ed imputed genotype data at 3,978,972 genome- 
wide SNPs in the same patients. Probes that corresponded to different genes (according to the 
GENCODE version 1919) were removed, and probes that corresponded to the same gene were 
combined as specified20. The final gene expression data set consisted of 17,008 probes. We note 
that the SNPs used for constructing the MATURA reference panel corresponded to a subset of 
the SNPs present within the UK data set, however, they did not correspond to an exact subset 
of SNPs present in the expanded European ancestry data set owing to different SNPs remaining 
post-QC. We used default PrediXcan parameters to build the elastic net model (α = 0.4, window 
size = 1 Mbp, false discovery rate threshold = 0.05). The final MATURA reference panel included 
1,573 genes. Models based on whole-blood GTEx and DGN reference panels were provided as part 
of the PrediXcan software (downloaded from http://predictdb.org/), and included 6,057 and 9,836 
genes, respectively. 
 
Replication analysis based on measured gene expression 
 
Clinical parameters including DAS28 score and subcomponents, ESR, CRP, rheumatoid factor 
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(RF) and anti-citrullinated peptide antibody (ACPA) positivity/titre were collected at baseline 
and every 3 months. Patients were treated with methotrexate-based combination DMARDs (81%), 
methotrexate alone (6.8%), hydroxychloroquine alone (5.9%) or sulfasalazine alone (3.4%) or no 
DMARDs (2.5%). Clinical response was assessed by change in clinical parameters at 6 months 
and correlated with IL18RAP transcript levels measured by RNA-seq in baseline synovial biopsy 
or whole blood. 
 
 
RESULTS 
 
Discovery analysis based on predicted gene expression 
 
The results for the UK and expanded European ancestry data sets are shown in figures 1 and 2, 
respectively. Although no genes pass experiment-wide significance, for the UK data set (figure 1), 
the most significant gene identified using the MATURA reference panel (IL18RAP on chromosome 
2) achieved close to experiment-wide significance (p = 4.3 × 10−5), and this was also the top gene 
when using the DGN reference panel (p = 6.7 × 10−5). When using the GTEx reference panel, 
IL18RAP was the fourth top gene (p = 1.5 × 10−3). 
For the expanded European ancestry data set (figure 2), IL18RAP was again the top gene 
when using the MATURA reference panel (p = 1.4 × 10−4). With the DGN reference panel, this 
gene was the fifth top gene (p = 2.3 × 10−4), and with the GTeX reference panel, it was the fourth 
top gene (p = 4.0 × 10−4). Online supplementary table 1 shows the significance levels and effect 
estimates achieved at IL18RAP when using either the full 3158-person expanded European 
ancestry cohort or when it is divided into its constituent UK or US/EU sub-cohorts. (Note that 
the results for the UK sub-cohort differ slightly from those obtained in the original analysis of 
the UK data set on account of (a) the different phenotypic adjustments made when using the 
full expanded European ancestry data set and (b) slightly different SNPs being available for 
prediction of expression, see below). The signal is seen to be predominantly driven by the 
results from the UK sub-cohort, with the US/EU sub-cohort showing the same direction of 
effect, but with the effect size considerably attenuated. 
The PrediXcan models for predicting the expression of IL18RAP involved 77, 46 and 86 SNPs 
when using the MATURA, GTEx and DGN reference panels, respectively (online 
supplementary table 2). All 77 SNPs from the MATURA reference panel appeared in the 
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expanded European ancestry data set, while 37 out of 46 SNPs from the GTEx reference panel 
and 82 out of 86 SNPs from the DGN reference panel appeared. Density estimates for the 
resulting predicted expression values are shown in online supplementary figure 1; their 
relationship with phenotype is shown in online supplementary figure 2. The prediction R2 
statistic for IL18RAP (based on PrediXcan’s internal tenfold cross-validation procedure using 
the relevant reference panel) was 0.32 (p = 1.9 × 10−19) with the MATURA reference panel, 0.30 
(p = 4.4 × 10−247) with the GTEx reference panel and 0.71 (p = 2.8 × 10−28) with the DGN 
reference panel, suggesting reasonable predictive ability for expression at this gene across all 
panels. As expected (given the association between SNPs contributing to the prediction models 
and expression, and between predicted expression and response), a number of SNPs also 
showed direct associations with response (online supplementary table S2), although as noted 
previously10 these do not meet genome-wide significance levels. 
 The most significant gene overall using the expanded European ancestry data set was 
ARV1 on chromosome 1, which appeared both when using the DGN reference panel (p = 9.1 × 
10−5) and the GTEx reference panel (p = 6.4 × 10−5). This gene was absent on the MATURA 
reference panel because the PrediXcan software failed to predict its expression value. In the 
original analysis of the UK data set, the signals for the ARV1 gene were generally weaker than, or 
similar to, those seen at IL18RAP (figure 1). Additionally, the prediction accuracy for ARV1 in  the 
expanded European ancestry data set, as measured by the R2 statistic, was very low (R2 = 9.6 × 
10−3; p = 0.072) with the GTEx reference panel, and relatively lower (R2 = 0.18; p = 2.1 × 10−41) 
than that seen for IL18RAP with the DGN reference panel, suggesting that these results at ARV1 
should be interpreted with caution. 
 
Replication analysis based on measured gene expression 
 
In the replication data set, we observed a significant expression quantitative trait locus (eQTL) 
association (P = 5.8 × 10−11) between multiple SNPs across the IL18RAP locus and IL18RAP 
expression measured by RNA-Seq of whole blood samples in patients with early RA (figure 3a, b), 
thus confirming that IL18RAP genetic polymorphisms regulate expression of IL18RAP in periph- 
eral blood in early RA patients. The expression of IL18RAP measured in whole blood showed cor- 
relation with the change in ESR between baseline and 6-month follow-up (r = −0.35; p = 0.0091) 
in RA patients treated with MTX-based combination DMARD therapy (figure 3c); specifically 
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each unit increase in IL18RAP regularised log expression resulted in a 13.4 mm/hour decrease 
in ESR between baseline and 6 months. Also, a correlation was observed between the expression 
of IL18RAP in synovial tissue and the change in ESR (r = −0.28; p = 0.02) (figure 3d); 
specifically each unit increase in regularised log expression resulted in a 11.8 mm/hour decrease 
in change in ESR over 6 months. Thus, our replication experiment based on actual measured 
gene expression (in an independent set of patients) validates the association between predicted 
IL18RAP expression and treatment response seen in the discovery cohort. 
 
 
 
DISCUSSION 
 
In this study, we investigated the association between the genetically-regulated portion of gene 
expression and change in the ESR in a large cohort of RA patients from the MATURA consor- 
tium. We found that predicted expression of IL18RAP showed a consistent signal across data sets 
analysed using different reference panels, while achieving a reasonable level of prediction accuracy 
as measured by the prediction R2. Despite the consistency of the results for IL18RAP, some 
differences in the strength of the signal were observed for different data sets and reference panels. 
These differences require further investigation, however they can be partly explained by the 
different sample sizes (and SNPs available to inform prediction) in the different reference panels. 
In an independent replication data set of patients treated with csDMARDs with measured gene 
expression, the asso- ciation between expression of IL18RAP and change in the ESR was confirmed 
both in whole-blood and synovial tissue, highlighting IL18RAP as a gene worthy of further 
investigation for prediction of treatment response in RA that is not treatment-specific. No other 
expressed genes were consistently associated with response, providing confidence that it is the 
IL18RAP gene that is driving the association rather than serving as a proxy for another gene. 
The protein encoded by IL18RAP enhances the IL-18 binding activity of the IL-18 receptor 
and plays a role in signaling by IL-18 21. IL-18 plays an inflammatory role in RA22, 23 and has 
previously been identified as a potential therapeutic target in the treatment of RA24, 25. It has been 
suggested that IL-18 plays some part in the degradation of articular cartilage in arthritis26. 
Additionally, Rooney et al.27 showed that synovial tissue IL-18 production measured by 
immunohistochemistry was correlated with serum C reactive protein in inflammatory arthritis, while 
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Joosten et al.28 found a correlation between the level of IL-18 in the synovial tissue of the RA 
patients and ESR. 
 
Previous studies have reported a potential association between IL18RAP and treatment 
response in RA. Analysis of CAGE sequencing data from the FANTOM5 consortium showed that 
IL18RAP is highly expressed in neutrophils, gamma delta T cells, eosinophils and NK cells29. 
Analysis of the BioGPS database (http://biogps.org/) confirms that IL18RAP is highly expressed 
in NK cells. IL18RAP expression is upregulated in NK and T cells in response to IFN-alpha and 
IL-1230. IL18RAP was found to be significantly upregulated (adjusted P = 5.5 × 10−78) in NK 
cells in single cell RNA-seq RA synovium data from Stephenson et al.31. Similarly in a second sin- 
gle cell RNA-seq study of RA synovium32, IL18RAP shows increased expression in synovial tissue 
T cell populations. In RA synovium, the baseline expression of the S1 module (NK cell surface 
signature) from Li et al.33 which includes IL18RAP as one of its 45 genes, correlates significantly 
with change in ESR. Additionally, the synovial baseline expression for another NK cell module 
(M7.2) which includes IL18RAP is also significant for the change in ESR.  
Our own investigation of the relationship between measured expression of IL18RAP and 
change in the ESR in whole-blood and synovial tissue in our replication data set was motivated by 
our initial identification of a relationship between change in the ESR and predicted expression of 
IL18RAP in our discovery data sets, using the PrediXcan method/software. Other 
methods/software packages for performing transcriptome-wide association studies exist, but as 
shown by Fryett et al34, they tend to perform very similarly to one another. These methods are 
dependent on the underlying eQTL data used to build the prediction models, and therefore 
would generally be expected to give very similar results. Given that the external datasets used to 
inform the prediction were derived from population studies and would unlikely to have been 
enriched for patients with RA, the risk of the association detected with ESR being spurious is 
low. 
We elected to focus on change in ESR as an objective measure of response that has been 
shown to have higher heritability than other measures of response9. Other clinical outcomes 
relating to anti-TNF treatment response, such as joint destruction scores or CRP, could certainly 
be assessed using similar approaches. However, joint destruction scores were not available in 
our discovery data set, and there were many missing values for CRP, making this a less attractive 
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option in this instance. 
Overall, our results, combined with the existing evidence, suggest that the expression of 
IL18RAP in whole blood might have utility for predicting response to treatment in RA. However, 
the effect observed in our replication samples (11.8-13.4 mm/hour decrease in change in ESR 
over 6 months) is, by itself, probably too small to be clinically useful, and the small to moderate 
correlations seen between IL18RAP expression and change in ESR (figure 3c, d) suggest that the 
actual predictive ability of IL18RAP expression alone may be limited. This approach shows the 
value of integrating genetic and expression data to identify factors correlated with response which 
could be incorporated into a multi-omic predictive model in the future. Further investigation of 
the relationship between IL18RAP expression and varying measures of treatment response in 
additional patient cohorts is thus warranted. 
 
 
Ackowledgements 
 
We thank all the patients who have contributed to this study as well as the research and clinical 
staff who supported patient recruitment. We thank the Medical Research Council and Arthritis 
Research UK (ARUK) for their joint funding of the MAximising Therapeutic Utility in Rheuma- 
toid Arthritis (MATURA) study. We thank MATURA consortium members for their input and 
feedback during the design of this project. 
 
 
Contributors 
 
Substantial contributions to conception or design of the study: SC, PM, JHB, CP, AB, HJC. 
Substantial contributions to drafting the manuscript: SC, MJL, HJC. Substantial contributions 
to data acquisition: CP, AB. Substantial contributions to data analysis or interpretation: SC, 
MJL, DP, NN, KG, ET, MRB. All authors contributed to revising the manuscript critically for 
important intellectual content and approved the final manuscript. The funding agencies had no 
part in writing or reviewing the manuscript. The views expressed are those of the authors and 
not necessarily those of the NIHR or the Department of Health and Social Care. 
12 
 
 
Funding 
 
Support for this work was provided by the Wellcome Trust (Grant 102858/Z/13/Z) and an 
MRC/Arthritis Research UK award: Maximizing Therapeutic Utility in RA (MATURA) (Grant 
MR-K015346). The Pathobiology of Early Arthritis Cohort (PEAC) was supported by funding 
from the Medical Research Council (MRC) (grant number G0800648). JHB receives support 
from the NIHR through the Leeds Biomedical Research Centre. This project was enabled through 
access to the MRC eMedLab Medical Bioinformatics infrastructure, supported by the Medical Re- 
search Council (grant number MR/L016311/1). We thank Arthritis Research UK (grant number 
20385) and the Musculoskeletal theme of the NIHR Manchester BRC for their support. 
 
 
Competing Interests 
 
The authors declare no competing interests. 
 
 
Patient and public involvement statement 
 
This study was conducted as part of the programme of work undertaken by the MATURA Consor- 
tium (http://www.matura.whri.qmul.ac.uk/). A patient advisory group was established in 2014 
when the MATURA project commenced. The group meets regularly to: ensure MATURA strat- 
egy is maintaining relevance, accountability and direction by embedding patients and members 
of the public within the decision making processes; determine what level of confidence in tests, 
and what type of tests, would be acceptable to patients for treatment decisions; maximise patient 
recruitment to research studies by increasing awareness through patient groups; readily obtain 
patients perspective on grant applications related to stratified medicines for RA; facilitate the 
dissemination of the results from MATURA research, for instance by producing lay summaries of 
papers in conjunction with the researchers (http://www.matura.whri.qmul.ac.uk/news.php). 
13 
 
 
Patient consent for publication 
 
Not required. 
 
 
Ethics approval 
 
This study used anonymised data for human subjects from an international collaboration of 13 
studies originally published in PLOS Genetics 2013;9:e1003394. All participants provided 
informed consent and institutional review board and ethics approvals were in place for each of 
the studies and described in the original publication. Approval for additional data pre- sented 
in this manuscript was provided by the North West 6 Central Manchester South Ethics 
Committee (COREC 04/Q1403/37) and the London–Dulwich Research Ethics Committee (REC 
05/Q0703/198). 
 
 
Data sharing statement 
 
Data are available upon reasonable request. 
14 
 
 
References 
 
[1] Barrera, P., van der Maas, A., van Ede, A. E., et al. (2002). Drug survival, efficacy and toxicity 
of monotherapy with a fully human anti-tumour necrosis factor-α antibody compared with 
methotrexate in long-standing rheumatoid arthritis. Rheumatology 41, 530–439. 
[2] Hyrich, K. L., Watson, K. D., Symmons, D. P., et al. (2006). Predictors of response to anti- 
TNF-α therapy among patients with rheumatoid arthritis: results from the British Society 
for Rheumatology Biologics Register. Rheumatology 45, 1558–1565. 
[3] Ha¨upl, T., Stuhlmu¨ller, B., Gru¨tzkau, A., et al. (2009). Does gene expression analysis inform 
us in rheumatoid arthritis? Ann Rheum Dis 69 (Suppl 1), i37–i42. 
[4] Tanino, M., Matoba, R., Nakamura, S., et al. (2009). Prediction of efficacy of anti-TNF 
biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcrip- 
tome analysis of white blood cells. Biochemical and Biophysical Research Communications 
387, 261–265. 
[5] Julia`, A., Erra, A., Palacio, C., et al. (2009). An eight-gene blood expression profile predicts 
the response to infliximab in rheumatoid arthritis. PLoS ONE 4, e7556. 
[6] Lequerre´, T., Gauthier-Jauneau, A.-C., Bansard, C., et al. (2006). Gene profiling in white blood 
cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Research & 
Therapy 8, R105. 
[7] Gamazon, E. R., Wheeler, H. E., Shah, K. P., et al. (2015). A gene-based association method 
for mapping traits using reference transcriptome data. Nature Genetics 47, 1091–1098. 
[8] Barton, A. and Pitzalis, C. (2017). Stratified medicine in rheumatoid arthritis – the MATURA 
programme: targeted treatment for patients. Rheumatology 56, 1247–1250. 
[9] Massey, J., Plant, D., Hyrich, K., et al. (2018). Genome-wide association study of response 
to tumour necrosis factor alpha inhibitor therapy in Rheumatoid Arthritis. The Pharmaco- 
genetics Journal 18, 657–664. 
15 
 
 
 
[10] Cherlin, S., Plant, D., Taylor, J. C., et al. (2018). Prediction of treatment response in 
rheumatoid arthritis patients using genomewide SNP data. Genetic Epidemiology 42, 754– 
771. 
[11] Anderson, C. A., Pettersson, F. H., Clarke, G. M., et al. (2010). Data quality control in 
genetic case-control association studies. Annals of the Rheumatic Diseases 5, 1564–1573. 
[12] Cui, J., Stahl, E. A., Saevarsdottir, S., et al. (2013). Genome-wide association study and 
gene expression analysis identifies CD84 as a predictor of response to Etanercept therapy in 
Rheumatoid Arthritis. PLOS Genetics 3, e1003394. 
[13] Lewis, M. J., Barnes, M. R., Blighe, K., et al. (2019). Molecular portraits of early rheumatoid 
arthritis identify clinical and treatment response phenotypes. Cell Rep 28, 2455–2470. 
[14] Shabalin, A. A. (2012). Matrix eQTL: ultra fast eQTL analysis via large matrix operations. 
Bioinformatics 28, 1353–1358. 
[15] Stegle, O., Parts, L., Piipari, M., et al. (2012). Using probabilistic estimation of expression 
residuals (PEER) to obtain increased power and interpretability of gene expression analyses. 
Nat Protoc 7, 500–507. 
[16] GTEx Consortium. (2013). The genotype-tissue expression (GTEx) project. Nature Genetics 
25, 580–585. 
 
[17] Battle, A., Mostafavi, S., Zhu, X., et al. (2014). Characterizing the genetic basis of tran- 
scriptome diversity through RNA-sequencing of 922 individuals. Genome Res 24, 14–24. 
[18] Johnson, W. E., Li, C., and Rabinovic, A. (2006). Adjusting batch effects in microarray 
expression data using empirical Bayes methods. Biostatistics 8, 118–127. 
[19] GENCODE (2019). https://www.gencodegenes.org/. Accessed: 2019-10-10. 
 
[20] Miller, J. A., Cai, C., Langfelder, P., et al. (2011). Strategies for aggregating gene expression 
data: the collapseRows R function. BMC Bioinformatics 12, 322. 
16 
 
 
 
[21] GENCARDS (2019). https://www.genecards.org/. Accessed: 2019-10-10. 
 
[22] Gracie, J. A., Forsey, R. J., Chan, W. L., et al. (1999). A proinflammatory role for IL-18 in 
rheumatoid arthritis. J Clin Invest 104, 1393–1401. 
[23] Liew, F. Y. and McInnes, I. B. (2002). Role of interleukin 15 and interleukin 18 in inflam- 
matory response. Ann Rheum Di 61 (Suppl 2), ii100–ii102. 
[24] Volin, M. V. and Koch, A. E. (2011). Interleukin-18: a mediator of inflammation and 
angiogenesis in rheumatoid arthritis. Journal of Interferon & Cytokine Research 31, 745–751. 
[25] McInnes, I. b., Liew, F. Y., and Gracie, J. A. (2004). Interleukin-18: a therapeutic target in 
rheumatoid arthritis? Arthritis Res Ther 7, 38–41. 
[26] Dai, S.-M., Shan, Z.-Z., Nishioka, K., et al. (2005). Implication of interleukin 18 in production 
of matrix metalloproteinases in articular chondrocytes in arthritis. Ann Rheum Dis 64, 735– 
742. 
[27] Rooney, T., Murphy, E., Benito, M., et al. (2004). Synovial tissue interleukin-18 expression 
and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis 63, 
1393–1398. 
[28] Joosten, L. A. B., Radstake, T. R. D., Lubberts, E., et al. (2003). Association of interleukin- 
18 expression with enhanced levels of both interleukin-1β and tumor necrosis factor α in knee 
synovial tissue of patients with rheumatoid arthritis. Arthritis & Rheumatism 48, 339–347. 
[29] FANTOM Consortium and the RIKEN PMI and CLST (DGT), Forrest, A. R., Kawaji, H., et 
al. (2014). A promoter-level mammalian expression atlas. Nature 507, 462–470. 
[30] Sareneva, T., Julkunen, I., and Matikainen, S. (2000). IFN-α and IL-12 induce IL-18 receptor 
gene expression in human NK and T cells. J Immunol 165, 1933–1938. 
[31] Stephenson, W., Donlin, L. T., Butler, A., et al. (2018). Single-cell RNA-seq of rheumatoid 
arthritis synovial tissue using low-cost microfluidic instrumentation. Nat Commun 9, 791. 
17 
 
 
 
[32] Zhang, F., Wei, K., Slowikowski, K., et al. (2019). Defining inflammatory cell states in 
rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass 
cytometry. Nat Immunol 20, 928–942. 
[33] Li, S., Rouphael, N., Duraisingham, S., et al. (2014). Molecular signatures of antibody 
responses derived from a systems biology study of five human vaccines. Nat Immunol 15, 
195–204. 
[34] Fryett, J.J, Inshaw, J., Morris, A.P., and Cordell, H.J. (2018). Comparison of methods for 
transcriptome imputation through application to two common complex diseases. Eur J 
Hum Genet 26, 1658–1667. 
18 
 
 
Figure Legends 
 
Figure 1: Manhattan plots of P -values from tests of association between genetically-regulated gene 
expression and the change in ESR for the 1575-person UK data set. The genetically-regulated gene 
expression was estimated with (a) the MATURA reference panel, (b) the GTEx reference panel, 
and (c) the DGN reference panel. On each panel, the red dashed line represents the experiment-
wide significance level computed using a Bonferroni correction for the number of tests performed. 
The black diamond represents the IL18RAP gene. The white diamond represents the ARV1 gene. 
 
 
Figure 2: Manhattan plots of P -values from tests of association between genetically-regulated gene 
expression and the change in ESR for the 3158-person expanded European ancestry data set. The 
genetically-regulated gene expression was estimated with (a) the MATURA reference panel, (b) 
the GTEx reference panel, and (c) the DGN reference panel. On each panel, the red dashed line 
represents the experiment-wide significance level computed using a Bonferroni correction for the 
number of tests performed. The black diamond represents the IL18RAP gene. The white diamond 
represents the ARV1 gene. 
 
 
Figure 3: Confirmation of the IL18RAP expression quantitative trait locus and clinical conse- 
quences in rheumatoid arthritis. (a) Manhattan plot showing expression quantitative trait locus 
analysis comparing influence of SNPs at the IL18RAP locus on IL18RAP expression in blood 
measured by RNA-seq. (b) Scatter plot of SNP rs10439410 in the 5’ upstream region of IL18RAP 
and IL18RAP expression in whole blood. (c & d) Correlation between the change in ESR between 
baseline and 6 months of combination DMARD therapy and IL18RAP expression measured by 
RNA-seq in whole blood (c) and synovial tissue (d). 
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Key messages 
 
What is already known about this subject? 
 
• IL-18 plays an inflammatory role in rheumatoid arthritis and has previously been 
identified as a potential therapeutic target. 
• The protein encoded by the gene IL18RAP enhances the IL-18-binding activity of the IL-
18 receptor and plays a role in IL-18 signaling. 
 
 
What does this study add? 
 
• We demonstrate a robust association between IL18RAP gene expression (both in whole- 
blood and synovial tissue) and treatment response in rheumatoid arthritis. 
• The association between IL18RAP expression and treatment response is not specific to a 
particular drug type but is observed across different treatments. 
 
How might this impact on clinical practice or future developments? 
 
• Measurements of IL18RAP expression could potentially be incorporated into a multi-omic 
predictive model for treatment response in rheumatoid arthritis in the future. 
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Table S1. E↵ect sizes and significance levels achieved at IL18RAP when using either the
full 3158-person expanded European ancestry cohort or when it is divided into its
constituent UK (1575 people) and US/EU (1583 people) sub-cohorts.
Reference panel Gene UK US/EU Full
E↵ect size P -value E↵ect size P -value E↵ect size P -value
MATURA IL18RAP -0.210 0.00021 -0.054 0.17344 -0.131 0.00014
GTEx IL18RAP -0.235 0.00105 -0.076 0.11999 -0.152 0.00040
DGN IL18RAP -0.128 0.00025 -0.030 0.21817 -0.079 0.00023
Table S2. The columns “E↵ect MATURA”, “E↵ect GTEx” and “E↵ect DGN” represent
the e↵ects of the SNPs in the prediction models when using the MATURA (77 SNPs),
GTEx (46 SNPs) and DGN (86 SNPs) reference panels. The columns “Coe↵” and
“P -value” represent the coe cient and the P -value from the association between the SNPs
and the phenotype in the UK data set.
SNP BP E↵ect MATURA E↵ect GTEx E↵ect DGN Coe↵ P -value
rs13413645 - - -0.040 - - -
rs6759556 - - 0.216 - - -
rs2310220 - - 0.094 - - -
rs11465677 - - -0.003 - - -
rs17775170 - - 0.009 - - -
rs10178585 - - -0.028 - - -
rs10185170 - - 0.068 - - -
rs12328682 - - 0.004 - - -
rs7599071 - - -0.010 - - -
rs1093515 - - - 0.015 - -
rs13427957 - - - -0.015 - -
rs266064 - - - -0.004 - -
rs4319952 - - - -0.021 - -
rs7589943 102038936 - 0.055 - 0.006 0.96600
rs290772 102126220 - - 0.007 -0.065 0.34800
rs75094400 102142042 0.080 - - -0.236 0.02390
rs17201799 102179247 - 0.054 - -0.038 0.37600
rs12990046 102543479 0.039 - - -0.007 0.85600
rs11678842 102674806 -0.010 - - 0.074 0.08400
rs13388182 102722402 - - -0.020 0.032 0.38700
rs13029804 102723017 - - 0.014 -0.072 0.11000
rs1812326 102860411 -0.031 - - 0.069 0.05930
rs10186746 102866377 -0.026 - - 0.065 0.07800
rs62151694 102899464 0.049 - - -0.072 0.25500
rs13007174 102960487 0.006 - - -0.081 0.17300
rs13014044 102961366 0.005 - - -0.087 0.14800
rs1946131 102961929 0.005 - - -0.077 0.19600
rs1054096 102962350 0.005 - - -0.079 0.18600
rs12989197 102962739 0.004 - - -0.075 0.21100
rs12996097 102963628 0.004 - - -0.081 0.17400
rs13028993 102963949 0.004 - - -0.076 0.20100
rs12999542 102965392 - - 0.017 -0.083 0.16300
rs13014644 102971363 0.015 - - -0.079 0.18500
rs13015714 102971865 - 0.018 - 0.111 0.00955
rs11465567 102978400 0.006 - - -0.072 0.22800
rs11465572 102980223 0.001 - - -0.071 0.23200
rs4134504 102982223 0.005 - - -0.081 0.17000
rs2058622 102985424 - - 0.016 0.112 0.00945
rs2058623 102986170 - - 0.015 0.113 0.00863
rs1465321 102986618 - - 0.002 0.113 0.00863
rs11465597 102987213 - - 0.006 -0.057 0.33600
rs10439410 102990788 0.007 - 0.031 -0.143 0.00005
rs6731157 102991191 0.006 - - -0.143 0.00005
rs6745614 102991213 0.007 - - -0.143 0.00005
rs6758936 102991369 0.007 - 0.016 -0.143 0.00005
rs2270297 102992675 - 0.011 0.050 0.115 0.00729
rs11465623 102993039 - 0.058 0.019 -0.020 0.76900
rs6753717 102993161 - 0.012 0.048 0.115 0.00729
rs2041739 102994333 0.012 - 0.018 -0.143 0.00006
rs6750020 102994714 - 0.013 0.046 0.114 0.00807
rs10208196 102996345 0.007 - 0.019 -0.143 0.00005
rs7556917 102997720 0.008 - - -0.143 0.00005
rs7584093 102997721 0.008 - - -0.143 0.00006
rs3213733 102997884 - - 0.001 -0.102 0.03120
rs3213732 102998279 0.008 - 0.021 -0.144 0.00005
rs10204757 102998974 0.008 - - -0.143 0.00005
rs6760621 102999952 0.008 - 0.021 -0.143 0.00005
rs11465641 103000868 0.009 - - -0.143 0.00005
rs17651485 103001650 - 0.057 0.086 -0.027 0.68000
rs3771161 103003961 - - 0.001 -0.099 0.03470
rs3771159 103004958 0.009 - - -0.143 0.00005
rs11903946 103005330 0.009 - - -0.143 0.00005
rs6706002 103006104 0.009 - 0.023 -0.143 0.00005
rs6749014 103006448 0.009 - 0.022 -0.144 0.00005
rs12712146 103008714 0.006 - - -0.156 0.00002
rs4851004 103009537 0.009 - 0.023 -0.144 0.00005
rs6732138 103009662 0.009 - - -0.146 0.00004
rs3771158 103009894 - - 0.018 -0.095 0.04320
rs1420096 103010912 0.009 - - -0.145 0.00005
rs2287033 103011237 0.009 - 0.022 -0.145 0.00005
rs1568681 103014696 -0.044 - - 0.118 0.00606
rs1420094 103015687 0.011 - 0.023 -0.143 0.00005
rs6710528 103016142 0.009 - 0.022 -0.142 0.00006
rs3732124 103018052 - - 0.022 -0.143 0.00005
rs4851571 103019000 - - 0.022 -0.144 0.00005
rs4851572 103019031 0.009 - 0.022 -0.144 0.00005
rs10202813 103019740 - - 0.014 -0.099 0.03460
rs1035129 103019785 0.009 - - -0.145 0.00005
rs1035127 103019919 -0.045 0.027 0.049 0.114 0.00767
rs6710034 103023678 0.010 - 0.021 -0.144 0.00005
rs7589142 103024660 0.010 - - -0.145 0.00004
rs4851007 103024813 -0.045 0.026 0.047 0.114 0.00767
rs4851575 103025203 -0.045 0.171 0.046 0.113 0.00811
rs10181785 103025274 - - 0.010 -0.097 0.03900
rs12712148 103025547 - - 0.007 -0.096 0.03990
rs11687768 103025738 - - 0.005 -0.096 0.04110
rs6543126 103027104 0.009 - - -0.144 0.00005
rs10203558 103027640 0.007 - 0.021 -0.144 0.00005
rs10200952 103027651 0.007 - 0.021 -0.143 0.00006
rs7586983 103028066 - - 0.008 -0.096 0.04110
rs6543127 103028301 0.009 - - -0.143 0.00005
rs4851576 103028895 0.012 - 0.022 -0.143 0.00005
rs4851577 103028921 0.017 - 0.021 -0.143 0.00005
rs4851579 103028984 0.009 - 0.021 -0.143 0.00005
rs6543132 103029410 -0.044 - - 0.114 0.00799
rs1807782 103033147 -0.017 0.023 0.045 0.115 0.00765
rs1035125 103033839 0.005 - - -0.143 0.00005
rs2160201 103033961 0.017 - - -0.143 0.00005
rs1420106 103035044 -0.043 0.022 0.045 0.113 0.00857
rs1420105 103035119 0.017 - 0.020 -0.143 0.00005
rs11465673 103035375 - - 0.010 -0.028 0.67400
rs2293223 103035468 - - 0.003 -0.097 0.03880
rs2293224 103035779 0.009 - 0.019 -0.143 0.00005
rs6756407 103036101 - - 0.011 -0.026 0.68800
rs6743516 103036335 0.009 - 0.019 -0.143 0.00005
rs1420100 103037002 0.008 - 0.019 -0.143 0.00005
rs3771155 103037826 0.009 - 0.021 -0.144 0.00005
rs3755267 103038587 -0.043 0.023 0.032 0.113 0.00860
rs10206291 103038863 0.009 - 0.030 -0.144 0.00005
rs885088 103039044 0.017 - 0.019 -0.143 0.00005
rs3771154 103039360 0.017 - 0.020 -0.143 0.00005
rs2272128 103039929 -0.042 0.023 0.029 0.116 0.00728
rs6759479 103040047 0.016 - 0.020 -0.143 0.00005
rs11465689 103040167 - - 0.036 -0.030 0.65000
rs12997015 103042401 0.002 - - 0.011 0.91800
rs3755266 103042712 - - 0.021 -0.143 0.00005
rs11694658 103045020 - - 0.006 0.108 0.01160
rs7559845 103046214 - - 0.021 -0.142 0.00006
rs2310300 103049074 - - 0.022 -0.142 0.00006
rs10166330 103050390 - - 0.009 -0.088 0.06110
rs3755265 103052816 - 0.052 0.018 -0.142 0.00006
rs10176820 103054420 - - 0.009 -0.089 0.05920
rs2058659 103054556 - 0.053 0.016 -0.142 0.00006
rs13021177 103056493 - 0.042 0.029 -0.143 0.00005
rs2075186 103057251 - - 0.002 -0.091 0.05410
rs11465736 103067930 - - 2.79e-05 -0.096 0.04130
rs17821875 103071030 - - 0.127 -0.014 0.82500
rs10169676 103074919 - - 2.87e-05 -0.089 0.05970
rs10210176 103079516 - - 0.001 -0.082 0.08120
rs10172116 103087573 - - 2.31e-04 -0.110 0.02050
rs1403552 103088777 - - 0.001 -0.088 0.06140
rs7597819 103092906 - - 0.021 0.113 0.00947
rs6737668 103093081 - 0.026 0.027 0.113 0.00941
rs10469840 103093243 - - 0.032 0.107 0.01430
rs759382 103094213 - 0.011 - 0.105 0.01420
rs9989749 103123642 - 0.033 - 0.065 0.15300
rs6751949 103125138 - 0.009 - 0.070 0.11200
rs4851607 103125632 - 0.002 - 0.079 0.07400
rs10195948 103125736 - 0.004 - 0.085 0.05510
rs2192757 103132378 - 0.004 - 0.080 0.06250
rs1916307 103134180 -0.042 - - 0.089 0.03680
rs1523203 103135759 - 0.020 - 0.082 0.05570
rs1403551 103136446 - 0.021 - 0.082 0.05510
rs4851613 103137990 - 0.021 - 0.084 0.05080
rs6750851 103138761 - 0.021 - 0.081 0.05790
rs6750971 103138825 - 0.021 - 0.083 0.05240
rs10193407 103139298 - 0.042 - 0.083 0.05350
rs17774619 103216776 0.115 - - -0.393 0.02020
rs1016160 103245025 - - 0.011 0.086 0.09020
rs17027893 103370379 - -0.008 - -0.022 0.65500
rs10172680 103376383 - -0.011 - -0.011 0.81800
rs2080294 103382425 - -0.012 - -0.012 0.81600
rs6705433 103386225 - -0.011 - -0.016 0.74600
rs6705568 103386368 - -0.010 - -0.014 0.77400
rs2310358 103413658 - -0.041 - -0.076 0.27400
rs75535834 103784955 0.154 - - 0.157 0.29300
rs6740972 103837781 0.028 - - -0.042 0.29600
rs7582789 103860075 -0.003 - - 0.126 0.20300
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Figure S1. Density estimates (calculated using the density() function in R) of the
predicted genetically-regulated gene expression at IL18RAP in the UK and expanded
European ancestry cohorts.
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Figure S2. Plots of the linear regressions that are being fitted at IL18RAP in the UK and
expanded European ancestry cohorts. Estimated regression lines are shown in red.
